{"title":"Bilirubin-Driven Phenotype Identifies Higher Mortality Risk in Severe Alcohol-Associated Hepatitis","authors":"Tewodros T. Ayele , Tomohiro Tanaka","doi":"10.1016/j.gastha.2026.100982","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Aims</h3><div>Among patients with severe alcohol-associated hepatitis (AH), the prognostic relevance of the dominant component of Maddrey’s Discriminant Function (MDF) is unclear.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study of adults with AH treated with corticosteroids at a US academic center (January 2016–December 2024). Using K-means clustering of the bilirubin and prothrombin time (PT) components of MDF, patients were classified into “PT-driven” vs “bilirubin-driven” phenotypes. The primary outcome was 90-day all-cause mortality. Inverse probability of treatment weighting-weighted Cox proportional hazards models were performed under an intention-to-treat framework, in which patients were not censored at liver transplantation. Secondary analyses used Fine-Gray competing risk models with liver transplantation as a competing event.</div></div><div><h3>Results</h3><div>Among 212 patients, 56 (26.4%) died within 90 days. Despite a similar Model for End-Stage Liver Disease, the bilirubin-driven group (n = 100) had significantly lower MDF scores and less hepatic encephalopathy compared to the PT-driven group (n = 112). Nevertheless, in the inverse probability of treatment weighting-weighted Cox proportional hazards model, the bilirubin-driven phenotype was associated with higher 90-day mortality (hazard ratio, 2.06; 95% confidence interval, 1.05–4.04). Findings were consistent in the Fine-Gray competing risks model (subdistribution hazard ratio, 2.11; 95% confidence interval, 1.03–4.35).</div></div><div><h3>Conclusion</h3><div>A bilirubin-dominant phenotype in severe AH was associated with significantly higher 90-day mortality, highlighting disease heterogeneity and suggesting potential value for risk stratification and for guiding future research on individualized care and optimal timing of liver transplant evaluation.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"5 7","pages":"Article 100982"},"PeriodicalIF":3.3000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastro hep advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772572326001032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/4/24 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background and Aims
Among patients with severe alcohol-associated hepatitis (AH), the prognostic relevance of the dominant component of Maddrey’s Discriminant Function (MDF) is unclear.
Methods
We conducted a retrospective cohort study of adults with AH treated with corticosteroids at a US academic center (January 2016–December 2024). Using K-means clustering of the bilirubin and prothrombin time (PT) components of MDF, patients were classified into “PT-driven” vs “bilirubin-driven” phenotypes. The primary outcome was 90-day all-cause mortality. Inverse probability of treatment weighting-weighted Cox proportional hazards models were performed under an intention-to-treat framework, in which patients were not censored at liver transplantation. Secondary analyses used Fine-Gray competing risk models with liver transplantation as a competing event.
Results
Among 212 patients, 56 (26.4%) died within 90 days. Despite a similar Model for End-Stage Liver Disease, the bilirubin-driven group (n = 100) had significantly lower MDF scores and less hepatic encephalopathy compared to the PT-driven group (n = 112). Nevertheless, in the inverse probability of treatment weighting-weighted Cox proportional hazards model, the bilirubin-driven phenotype was associated with higher 90-day mortality (hazard ratio, 2.06; 95% confidence interval, 1.05–4.04). Findings were consistent in the Fine-Gray competing risks model (subdistribution hazard ratio, 2.11; 95% confidence interval, 1.03–4.35).
Conclusion
A bilirubin-dominant phenotype in severe AH was associated with significantly higher 90-day mortality, highlighting disease heterogeneity and suggesting potential value for risk stratification and for guiding future research on individualized care and optimal timing of liver transplant evaluation.